Physical Examination Center, Hebei General Hospital, Shijiazhuang City, Hebei Province, China.
Department of Hepatobiliary Surgery, Hebei General Hospital, Shijiazhuang City, Hebei Province, China.
Sci Rep. 2024 May 15;14(1):11170. doi: 10.1038/s41598-024-62124-w.
Asprosin, an adipokine, was recently discovered in 2016. Here, the correlation between asprosin and metabolic-associated fatty liver disease (MAFLD) was examined by quantitatively assessing hepatic steatosis using transient elastography and controlled attenuation parameter (CAP). According to body mass index (BMI), 1276 adult participants were enrolled and categorized into three groups: normal, overweight, and obese. The study collected and evaluated serum asprosin levels, general biochemical indices, liver stiffness measure, and CAP via statistical analysis. In both overweight and obese groups, serum asprosin and CAP were greater than in the normal group (p < 0.01). Each group showed a positive correlation of CAP with asprosin (p < 0.01). The normal group demonstrated a significant and independent positive relationship of CAP with BMI, low-density lipoprotein cholesterol (LDL-C), asprosin, waist circumference (WC), and triglycerides (TG; p < 0.05). CAP showed an independent positive association (p < 0.05) with BMI, WC, asprosin, fasting blood glucose (FBG), and TG in the overweight group, and with high-density lipoprotein cholesterol (HDL-C) showed an independent negative link (p < 0.01). CAP showed an independent positive relationship (p < 0.05) with BMI, WC, asprosin, TG, LDL-C, FBG, glycated hemoglobin A1c (HbA1c), and alanine transferase in the obese group. CAP also showed an independent positive link (p < 0.01) with BMI, WC, asprosin, TG, LDL-C, and FBG in all participants while independently and negatively correlated (p < 0.01) with HDL-C. Since asprosin and MAFLD are closely related and asprosin is an independent CAP effector, it may offer a novel treatment option for metabolic diseases and MAFLD.
阿普斯素是一种脂肪细胞因子，于 2016 年被发现。本研究通过瞬时弹性成像和受控衰减参数（CAP）定量评估肝脂肪变性来检查阿普斯素与代谢相关脂肪性肝病（MAFLD）之间的相关性。根据体重指数（BMI），纳入 1276 名成年参与者，并将其分为三组：正常、超重和肥胖。研究通过统计分析收集和评估血清阿普斯素水平、一般生化指标、肝硬度测量值和 CAP。在超重和肥胖组中，血清阿普斯素和 CAP 均高于正常组（p<0.01）。各组 CAP 与阿普斯素均呈正相关（p<0.01）。正常组 CAP 与 BMI、低密度脂蛋白胆固醇（LDL-C）、阿普斯素、腰围（WC）和三酰甘油（TG）呈显著独立的正相关（p<0.05）。在超重组中，CAP 与 BMI、WC、阿普斯素、空腹血糖（FBG）和 TG 呈独立正相关（p<0.05），而与高密度脂蛋白胆固醇（HDL-C）呈独立负相关（p<0.01）。在肥胖组中，CAP 与 BMI、WC、阿普斯素、TG、LDL-C、FBG、糖化血红蛋白 A1c（HbA1c）和丙氨酸转氨酶呈独立正相关（p<0.05）。在所有参与者中，CAP 与 BMI、WC、阿普斯素、TG、LDL-C 和 FBG 呈独立正相关（p<0.05），与 HDL-C 呈独立负相关（p<0.01）。由于阿普斯素与 MAFLD 密切相关，且阿普斯素是 CAP 的独立效应物，因此它可能为代谢性疾病和 MAFLD 提供一种新的治疗选择。
